CTI regains compliance with all applicable NASDAQ listing standards

Download PDF Copy

Jun 1 2011

NewsGuard 100/100 Score

Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced that it has received a letter from The NASDAQ Stock Market LLC (the "NASDAQ"), indicating that CTI has regained compliance with the minimum bid price rule (i.e., NASDAQ Listing Rule 5550(a)(2)) for continued listing on The NASDAQ Capital Market and that CTI is in compliance with all applicable listing standards. Therefore, the scheduled hearing, which CTI previously announced in a press release dated May 6, 2011, before the NASDAQ Listing Qualifications Panel has been cancelled and CTI's common stock will continue to be listed and traded on The NASDAQ Stock Market.

SOURCE Cell Therapeutics, Inc.

Posted in: Business / Finance

Tags: B Cell, Cancer, Cell, Hearing, Oncology, T-Cell, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Neuropeptides influence T cell differentiation during viral infections

Neuropeptides influence T cell differentiation during viral infections

MD Anderson launches new institute for advancing cell therapy

MD Anderson launches new institute for advancing cell therapy

Single-cell study identifies pro-metastatic cell subpopulations

Single-cell study identifies pro-metastatic cell subpopulations

Scientists develop first durable human lip cell models in the lab

Scientists develop first durable human lip cell models in the lab

Groundbreaking study sheds light on stem cell dynamics post-transplant

Groundbreaking study sheds light on stem cell dynamics post-transplant

Assessing recurrence risk with ctDNA-based MRD detection in NSCLC patients

Assessing recurrence risk with ctDNA-based MRD detection in NSCLC patients

Stem-cell implants restore vision in patients with corneal stem cell deficiency

Stem-cell implants restore vision in patients with corneal stem cell deficiency

Space-grown stem cells show promise for accelerating biotherapies

Space-grown stem cells show promise for accelerating biotherapies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension